Acurx Pharmaceuticals, Inc.

ACXP Nasdaq SEC CIK 1736243
Follow Acurx Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$2.6M −29.6% vs same quarter last year
EPS, diluted −$0.49 +60.2% vs same quarter last year
Operating cash flow −$2.5M −32.3% vs same quarter last year
Operating income −$2.6M −29.7% vs same quarter last year
Net income by quarter
−$2.8M
−$2.1M
−$2.2M
−$2M
−$1.6M
−$1.7M
−$2.3M
−$2.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$15M−$10M−$5M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$8M
FY24−$14.1M
FY23−$14.6M
FY22−$12.1M
FY21−$12.7M
FY20−$4.6M
FY19-